ReviewCurrent cardiology reports2015
FDG PET imaging for identifying pulmonary hypertension and right heart failure.
Review in Current cardiology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Pulmonary ParenchymalJournal of clinical medicine · 2026Article
- Multi-organ metabolic connectivity mapping in advanced pulmonary arterial hypertension: a group-level 18 F-FDG PET-controlled study.BMC medical imaging · 2026Article
- Test-retest Assessment of Biventricular Myocardial Oxidative Metabolism and Perfusion in Pulmonary Hypertension Patients UsingMolecular imaging and biology · 2025Article
- Glycolysis modulation: New therapeutic strategies to improve pulmonary hypertension (Review).International journal of molecular medicine · 2024Review
- Magnetic nanoradiotracers for targeted neutrophil detection in pulmonary arterial hypertension.Journal of nanobiotechnology · 2024Article
- Early detection of pulmonary arterial hypertension through [Pulmonary circulation · 2024Article
- Sarcoidosis Associated Pulmonary Hypertension.Biomedicines · 2024Review
- Non-invasive imaging techniques for early diagnosis of bilateral cardiac dysfunction in pulmonary hypertension: current crests, future peaks.Frontiers in cardiovascular medicine · 2024Review
- Effects of ranolazine on right ventricular function, fluid dynamics, and metabolism in patients with precapillary pulmonary hypertension: insights from a longitudinal, randomized, double-blinded, placebo controlled, multicenter study.Frontiers in cardiovascular medicine · 2023Article
- Long-Term Study on Therapeutic Strategy for Treatment of Eisenmenger Syndrome Patients: A Case Series Study.Children (Basel, Switzerland) · 2022Article
- The role of imaging in pulmonary hypertension.Cardiovascular diagnosis and therapy · 2021Review
- Article
- Non-invasive Multimodality Cardiovascular Imaging of the Right Heart and Pulmonary Circulation in Pulmonary Hypertension.Frontiers in cardiovascular medicine · 2019Review
- Recurrent inhibition of mitochondrial complex III induces chronic pulmonary vasoconstriction and glycolytic switch in the rat lung.Respiratory research · 2018Article
- Molecular imaging of cardiac remodelling after myocardial infarction.Basic research in cardiology · 2018Review
- Evaluation of the hemodynamics and right ventricular function in pulmonary hypertension by echocardiography compared with right-sided heart catheterization.Experimental and therapeutic medicine · 2017Article
- Platelets from pulmonary hypertension patients show increased mitochondrial reserve capacity.JCI insight · 2017Article
- Imaging the heart in pulmonary hypertension: an update.European respiratory review : an official journal of the European Respiratory Society · 2015Review
- The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers.Pulmonary circulationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is a syndrome characterized by lung vascular intimal lesions, smooth muscle layer hypertrophy, perivascular inflammation, and concomitant right ventricular (RV) remodeling which can ultimately lead to the RV function decline known as RV failure (RVF). A key determining factor for RVF development is the RV metabolic state defined by the level of ischemia and glycolysis which constitute a vicious cycle of hypoxia, metabolic shift from glucose oxidation (GO) to glycolysis, increased RV systolic pressure (RVSP), decreased RV output, and further myocardial ischemia. In this context, 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) positron emission tomography (PET) has been used for the measurement of glucose uptake (GU) as an indicator of glucose metabolism in the right heart and pulmonary vasculature. The focus of this review is the application of FDG PET modality for assessing PAH severity and clinical outcome.
Indexed as
Identifiers
25504422What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.